HOME >> MEDICINE >> NEWS
Data supports extremely early intervention for multiple sclerosis patients

et will go on to develop typical MS. Consequently, a second occurrence of MS symptoms involving another part of the nervous system or definite new abnormalities that appear on magnetic resonance imaging (MRI) of the brain and spinal cord are required in order to make a definite MS diagnosis.

This study, involving patients from 32 sites across the U.S. over a five-year period, was designed to determine if much earlier treatment within a month of the appearance of initial symptoms and before a definite diagnosis had been made would delay the onset of new neurological symptoms compared to initiation of therapy more than two years after the onset of symptoms.

"The study actually evolved from an earlier investigation, known as the CHAMPS study," explains Kinkel. CHAMPS, a two-year blinded placebo controlled trial in which 383 MS patients were treated weekly with either Avonex or a placebo, found that those individuals who received Avonex experienced a 44 percent decrease in the rate of developing a second MS attack that would qualify them for a diagnosis of MS compared with the patients who received a placebo.

"We were extremely pleased with the outcome of the CHAMPS trial," notes Kinkel. "But we realized that because disabling MS symptoms such as difficulty walking and thinking that does not improve may not appear in patients for many years. We would have to conduct a much longer study to determine if Avonex actually slowed the progression of these debilitating symptoms."

To test the medication's long-term effectiveness, the study followed 203 patients, half of whom had been receiving Avonex from the onset of the CHAMPS trial (immediately after demonstrating MS symptoms) and half of whom began treatment with Avonex at a later point, following their second MS attack (or two or more years after their first attack). The study found that patients who began treatment with Avonex immediately after their first attack had a 35 perce
'"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
20-Sep-2003


Page: 1 2 3

Related medicine news :

1. Emergency department study supports giving dehydrated children fluids by mouth
2. Review supports link between HRT and stroke
3. Chamomile tea: New evidence supports health benefits
4. Social supports lessen effects of maltreatment on children vulnerable to depression
5. Study supports the use of mechanical assistance
6. Study supports aggressive treatment of heart patients with cholesterol-lowering medication
7. New data supports CellCepts position as a world leader in solid organ transplantation
8. NCI grant supports Jefferson trial to study test for colorectal cancer recurrence
9. Study supports new theory for nicotines protective effect against neurodegenerative disorders
10. New study supports use of PET scans in early diagnosis of Alzheimers disease
11. Contraception study supports convenience, simplicity

Post Your Comments:
(Date:6/29/2015)... CA (PRWEB) , ... June 29, 2015 , ... ... and imprinted accessories, is offering discounted pricing on all purchases that include branding. ... foundation of a brand is the logo. The website, packaging and promotional materials, all ...
(Date:6/29/2015)... VA (PRWEB) , ... June 29, 2015 , ... ... services to government contractors, nonprofits, independent schools, and other growing businesses across the ... Insights Top 100 Value Added Resellers for the fifth consecutive year. , Based ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors and Usability Studies: ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors , The ... to the design of new products as well as to postmarket surveillance of ...
(Date:6/29/2015)... , ... June 29, 2015 , ... People across the country give their coworkers and ... part of our culture. , But, how often do coworkers donate “life” to the ... a simple one. , “Dawna (Wright-Thompson) told me her husband was on a ...
(Date:6/29/2015)... ... June 29, 2015 , ... Two ... against C.R. Bard, Inc. and Ethicon, Inc. continue to move forward in New ... Management Conference is to be convened on Thursday, July 23rd at 12:00 p.m. ...
Breaking Medicine News(10 mins):Health News:Stock Up on Logo Branding Tools Reduced this Month and Next Month from Displays and Exhibits 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4
(Date:6/29/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... is now included in the Russell 3000®, the Russell ... to the indexes occurred at the close of trading ... its comprehensive set of U.S. and global indexes. ... Cap and Global Indexes coincides with the progress we ...
(Date:6/29/2015)... , June 29, 2015  Relmada Therapeutics, ... therapies for the treatment of chronic pain, announced ... study with novel formulations of oral, enteric-coated buprenorphine ... chronic pain and opioid dependence indications has reached ... company anticipates reporting top-line results in the second ...
(Date:6/29/2015)... England , June 29, 2015  Eli ... Immunocore Limited today announced that they have entered ... the utility of Immunocore,s lead T cell receptor-based ... (LY2157299) and merestinib (LY2801653) for the treatment of ... identify combination regimens that provide synergies in efficacy ...
Breaking Medicine Technology:Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 2Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 3Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 2Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 2Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 4Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 5Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 6Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 7
Cached News: